Antibody treatment added to HIV meds for early HIV
Part of Immune system & allergy, Infections clinical trials.
This Phase 2 trial tests whether adding long-acting HIV antibodies to standard HIV treatment (ART) can help control HIV in people who started ART soon after getting infected. It also checks how safe the antibody treatment is and how well it works over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 60 years old
- You must be able to sign consent and attend regular study visits with blood tests
- You must have started HIV treatment within 6 months of becoming infected
- You must have strong immune health: recent CD4 count above 500 (or CD4:CD8 ratio above 1)
- You must be on HIV treatment that includes an integrase inhibitor or a boosted protease inhibitor at enrollment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
This trial tests whether giving two powerful HIV-fighting antibodies (called broadly neutralizing monoclonal antibodies) along with starting standard HIV medications soon after infection can help control the virus without needing daily pills. If successful, it might allow people to take a 'treatment pause' while keeping their immune system healthy.
This study tests if two lab-made antibodies can keep HIV under control when people temporarily stop their daily HIV medication. Participants will pause their antiretroviral therapy (ART) for a period and be closely monitored, with the goal of potentially finding a way to take a break from daily pills.
This trial tests whether a combination of powerful antibodies (bNAbs) can help control HIV after stopping standard HIV treatment. Participants will pause their daily HIV medications while receiving these antibodies, and doctors will closely monitor their immune system and virus levels. It's for people who are already well-controlled on HIV treatment and have participated in a specific earlier study.
This Phase 3 study looks at antiretroviral treatment (HIV medicines) for adults with either recent (acute) or long-term (chronic) HIV. It’s designed to see how well and safely ongoing HIV treatment works, and it may help you get structured care and monitoring.
This study tests a new combination medicine for people with HIV who have never taken treatment. It aims to see if it is safe and helps reduce the amount of virus in the blood.
Hear when a new HIV/AIDS and Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.